ProPhase Labs, Inc. Interest Paid, Excluding Capitalized Interest, Operating Activities
ProPhase Labs, Inc. (PRPH) reported Interest Paid, Excluding Capitalized Interest, Operating Activities of $30.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:InterestPaidNet · last filed 2026-08-19
- ProPhase Labs, Inc. interest paid, excluding capitalized interest, operating activities for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- ProPhase Labs, Inc. interest paid, excluding capitalized interest, operating activities for the quarter ending 2026-03-31 was $30.00K, a 92.02% decline year-over-year.
- ProPhase Labs, Inc. interest paid, excluding capitalized interest, operating activities for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- ProPhase Labs, Inc. interest paid, excluding capitalized interest, operating activities for the quarter ending 2025-09-30 was $489.00K, a 44.99% decline year-over-year.
- ProPhase Labs, Inc. interest paid, excluding capitalized interest, operating activities for fiscal 2025 was $1.16M, a 62.61% decline from fiscal 2024.
- ProPhase Labs, Inc. interest paid, excluding capitalized interest, operating activities for fiscal 2024 was $3.10M, a 233.15% increase from fiscal 2023.
- ProPhase Labs, Inc. interest paid, excluding capitalized interest, operating activities for fiscal 2023 was $932.00K, a 22.15% increase from fiscal 2022.
- ProPhase Labs, Inc. interest paid, excluding capitalized interest, operating activities for fiscal 2022 was $763.00K, a 23.70% decline from fiscal 2021.
| Period end | Interest Paid, Excluding Capitalized Interest, Operating Activities 3 month | Interest Paid, Excluding Capitalized Interest, Operating Activities 6 month | Interest Paid, Excluding Capitalized Interest, Operating Activities 9 month | Interest Paid, Excluding Capitalized Interest, Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-19 | $30.00K 10-Q · filed 2026-08-19 | $30.00K derived: sum of 3 quarters · filed 2026-08-19 | $519.00K derived: sum of 4 quarters · filed 2026-08-19 |
| 2026-03-31 | $30.00K 10-Q/A · filed 2026-07-09 | $30.00K derived: sum of 2 quarters · filed 2026-07-09 | $519.00K derived: sum of 3 quarters · filed 2026-07-09 | $815.00K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $489.00K derived: sum of 2 quarters · filed 2026-06-01 | $785.00K derived: sum of 3 quarters · filed 2026-08-19 | $1.16M 10-K · filed 2026-06-01 |
| 2025-09-30 | $489.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | $785.00K derived: sum of 2 quarters · filed 2026-08-19 | $1.16M 10-Q · filed 2025-11-19 | $2.14M derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-06-30 | $296.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-19 | $672.00K 10-Q · filed 2026-08-19 | $1.65M derived: sum of 3 quarters · filed 2026-08-19 | $2.54M derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-03-31 | $376.00K 10-Q/A · filed 2026-07-09 | $1.35M derived: sum of 2 quarters · filed 2026-07-09 | $2.24M derived: sum of 3 quarters · filed 2026-07-09 | $2.84M derived: sum of 4 quarters · filed 2026-07-09 |
| 2024-12-31 | $979.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $1.87M derived: sum of 2 quarters · filed 2026-06-01 | $2.46M derived: sum of 3 quarters · filed 2026-06-01 | $3.10M 10-K · filed 2026-06-01 |
| 2024-09-30 | $889.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | $1.48M derived: sum of 2 quarters · filed 2025-11-19 | $2.13M 10-Q · filed 2025-11-19 | $2.32M derived: sum of 4 quarters · filed 2025-11-19 |
| 2024-06-30 | $595.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $1.24M 10-Q · filed 2025-08-13 | $1.43M derived: sum of 3 quarters · filed 2025-08-13 | $1.48M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $642.00K 10-Q · filed 2025-05-20 | $834.00K derived: sum of 2 quarters · filed 2025-05-20 | $884.00K derived: sum of 3 quarters · filed 2025-05-20 | $1.37M derived: sum of 4 quarters · filed 2025-05-20 |
| 2023-12-31 | $192.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-01 | $242.00K derived: sum of 2 quarters · filed 2025-04-01 | $729.00K derived: sum of 3 quarters · filed 2025-04-01 | $932.00K 10-K · filed 2025-04-01 |
| 2023-09-30 | $50.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $537.00K derived: sum of 2 quarters · filed 2024-11-13 | $740.00K 10-Q · filed 2024-11-13 | $872.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $487.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $690.00K 10-Q · filed 2024-08-14 | $822.00K derived: sum of 3 quarters · filed 2024-08-14 | $1.01M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $203.00K 10-Q · filed 2024-05-10 | $335.00K derived: sum of 2 quarters · filed 2024-05-10 | $525.00K derived: sum of 3 quarters · filed 2024-05-10 | $725.00K derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $132.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $322.00K derived: sum of 2 quarters · filed 2024-03-29 | $522.00K derived: sum of 3 quarters · filed 2024-03-29 | $763.00K 10-K · filed 2024-03-29 |
| 2022-09-30 | $190.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $390.00K derived: sum of 2 quarters · filed 2023-11-13 | $631.00K 10-Q · filed 2023-11-13 | $881.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $200.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $441.00K 10-Q · filed 2023-08-11 | $691.00K derived: sum of 3 quarters · filed 2023-08-11 | $941.00K derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $241.00K 10-Q · filed 2023-05-12 | $491.00K derived: sum of 2 quarters · filed 2023-05-12 | $741.00K derived: sum of 3 quarters · filed 2023-05-12 | $991.00K derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $250.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $500.00K derived: sum of 2 quarters · filed 2023-03-29 | $750.00K derived: sum of 3 quarters · filed 2023-03-29 | $1.00M 10-K · filed 2023-03-29 |
| 2021-09-30 | $250.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $500.00K derived: sum of 2 quarters · filed 2022-11-10 | $750.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $250.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $500.00K 10-Q · filed 2022-08-12 | ||
| 2021-03-31 | $250.00K 10-Q · filed 2022-05-13 | |||
| 2020-12-31 | $250.00K 10-K · filed 2022-03-31 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | $0.00 derived: sum of 2 quarters · filed 2019-03-26 | $0.00 derived: sum of 3 quarters · filed 2019-03-26 | $54.00K 10-K · filed 2019-03-26 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q/A 6 month · filed 2018-11-14 | $0.00 derived: sum of 2 quarters · filed 2018-11-14 | $54.00K 10-Q · filed 2018-11-14 | $149.00K derived: sum of 4 quarters · filed 2018-11-14 |
| 2017-06-30 | $0.00 derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2018-08-20 | $54.00K 10-Q/A · filed 2018-08-20 | $149.00K derived: sum of 3 quarters · filed 2018-08-20 | $149.00K derived: sum of 4 quarters · filed 2018-08-20 |
| 2017-03-31 | $54.00K 10-Q/A · filed 2018-08-20 | $149.00K derived: sum of 2 quarters · filed 2018-08-20 | $149.00K derived: sum of 3 quarters · filed 2018-08-20 | |
| 2016-12-31 | $95.00K derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2018-08-20 | $95.00K derived: sum of 2 quarters · filed 2018-08-20 | $190.00K 10-K/A · filed 2018-08-20 | |
| 2016-09-30 | $0.00 derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2018-08-20 | $95.00K 10-Q/A · filed 2018-08-20 | ||
| 2016-06-30 | $95.00K 10-Q/A · filed 2018-08-20 | |||
| 2015-12-31 | $6.00K 10-K/A · filed 2018-08-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |